The Rise in Robotic Atypical Segmentectomies
Launched by M.D. ANDERSON CANCER CENTER · Nov 19, 2020
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the growing use of robotic surgery techniques for a procedure called atypical segmentectomy, which involves removing a specific section of the lung to treat lung cancer. Researchers are reviewing medical records of patients who had lung surgery from 2004 to 2019 to see if using robotic methods has increased the number of these surgeries. The goal is to understand how effective and safe this approach is compared to traditional surgery.
Anyone who has had lung surgery during this period may be eligible to participate in the study, regardless of their age or gender. If you or a family member qualify, you can expect to provide information about your past treatment, and your medical data will be analyzed to help improve future lung cancer surgeries. It’s important to know that this study is currently recruiting participants, so there may be opportunities to get involved if you meet the criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who underwent a lung resection from 2004 to 2019
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
David C Rice
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials